Amicus Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Amicus Therapeutics generated cash of -$69,091,000, which is more than the previous year. Cash used in financing activities reached the amount of $61,677,000 last year. Net change in cash is therefore $96,962,000.
Cash Flow
| 2014 | -51.66M | -107.07M | 139.17M |
|---|---|---|---|
| 2015 | -100.13M | -145.34M | 290.89M |
| 2016 | -150.53M | -4.50M | 272.71M |
| 2017 | -215.48M | -171.24M | 247.43M |
| 2018 | -299.95M | -121.2M | 450.77M |
| 2019 | -250.41M | 95.15M | 217.50M |
| 2020 | -233.29M | -13.57M | 262.85M |
| 2021 | -202.49M | 78.76M | 212.07M |
| 2022 | -166.57M | 92.31M | -7.46M |
| 2023 | -69.09M | 98.06M | 61.67M |
FOLD Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 153.11M | 249.45M | 166.16M | 146.34M | 82.37M | 51.23M | 187.02M | 69.48M | 24.07M | 43.64M |
Operating activities | ||||||||||
Net income | -151.58M | -236.56M | -250.46M | -276.85M | -356.38M | -348.99M | -284.00M | -200.04M | -132.11M | -68.92M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 7.87M | 5.34M | 6.20M | 8.84M | 4.77M | 4.21M | 3.59M | 3.24M | 1.83M | 1.54M |
Stock-based compensation expense | 86.07M | 76.51M | 57.83M | 49.15M | 44.43M | 0 | 23.10M | 17.50M | 9.97M | 6.00M |
| Deferred income tax benefit | 86.07M | 76.51M | 57.83M | 49.15M | 44.43M | 0 | 23.10M | 17.50M | 9.97M | 6.00M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -20.10M | -17.33M | -8.18M | -11.21M | -11.11M | -13.29M | -7.72M | -1.41M | 0 | 1.08M |
Inventories | -44.61M | -5.34M | -7.79M | -4.63M | -5.11M | -4.20M | -897K | -3.65M | 0 | 2.29M |
Accounts payable | 49.19M | -6.37M | 7.43M | -10.61M | 46.74M | 17.11M | 12.56M | 7.13M | 15.46M | 6.16M |
Cash generated by operating activities | -69.09M | -166.57M | -202.49M | -233.29M | -250.41M | -299.95M | -215.48M | -150.53M | -100.13M | -51.66M |
Investing activities | ||||||||||
Purchases Of Investments | -91.72M | -243.25M | -341.39M | -365.17M | -383.88M | -578.39M | -490.46M | -219.93M | -289.59M | -162.75M |
Investments In Property Plant And Equipment | -7.44M | -3.76M | -3.88M | -3.22M | -20.01M | -6.30M | -4.52M | -5.95M | -4.81M | -238K |
Acquisitions Net | 0 | 3.41M | 3.88M | 3.22M | 20.01M | 6.30M | 0 | 0 | -141.06M | 0 |
Cash generated by investing activities | 98.06M | 92.31M | 78.76M | -13.57M | 95.15M | -121.2M | -171.24M | -4.50M | -145.34M | -107.07M |
Financing activities | ||||||||||
Common Stock Issued | 92.93M | 4.31M | 199.75M | 42.28M | 188.99M | 294.58M | 243.03M | 97.06M | 243.04M | 135.80M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | -11.49M | -15.00M | -10.02M | -3.23M | 0 | -1.59M | 0 | -2.04M | 0 |
Repayments of term debt | -20.95M | -283K | -479K | -155.32M | 19.45M | -334K | -308K | -80.19M | 34.70M | -299K |
Cash used in financing activities | 61.67M | -7.46M | 212.07M | 262.85M | 217.50M | 450.77M | 247.43M | 272.71M | 290.89M | 139.17M |
Net Change In Cash | 96.96M | -96.34M | 83.29M | 19.81M | 63.96M | 31.13M | -137.96M | 117.54M | 45.41M | -19.56M |
Cash at end of period | 250.07M | 153.11M | 249.45M | 166.16M | 146.34M | 82.37M | 49.06M | 187.02M | 69.48M | 24.07M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |